Clinical Trial Update: Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) [Phase 1, Phase 2]

View source ↗

Summary

This update describes an ongoing Phase 1/Phase 2 trial evaluating the maximum tolerated dose, safety, and early efficacy of rhenium nanoliposomes in recurrent g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Rhenium Nanoliposomes (rhenium nanoliposome)

Snippet

Sponsor: Plus Therapeutics | Conditions: Glioma | Phase 1, Phase 2 | Status: RECRUITING